Table 1.
Baseline Demographic and Clinical Characteristics.
| Patients | N (%) |
|---|---|
| N° of patients | 44 |
| Sex: Male, N (%) | 44 (100.00% |
| Age, Median (Range) | 35.93 (12–72) |
| Clinical characteristics | |
| Haemophilia severity, N (%) | |
| Severe | 42 (95.45%) |
| Moderate | 1 (2.27%) |
| Mild | 1 (2.27%) |
| Patient with target joint, N (%) | 25 (56.82%) |
| Prophylaxis regimen, N (%) | 44 (100.0%) |
| Prophylaxis duration (year), Median (Range) | 9.0 (1–20) |
| Products used in the 12 months before BAY 81-8973, N (%) | |
| Kogenate FS | 33 (75.00%) |
| Helixate Nexgen | 8 (18.18%) |
| Advate | 1 (2.27%) |
| Refacto AF | 1 (2.27%) |
| More than one product | 1 (2.27%) |